Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CADUET vs NEVANAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Treatment of pain and inflammation associated with cataract surgery,Reduction of risk of macular edema following cataract surgery
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Nepafenac is metabolized via ocular tissues to amfenac, the active metabolite. Systemic metabolism primarily involves hepatic conjugation and oxidation.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
Nepafenac is approximately 98% bound to plasma proteins, primarily albumin.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
The apparent volume of distribution (Vd/F) is approximately 0.6 L/kg (range 0.5-0.7 L/kg), suggesting distribution into total body water and some tissue binding.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
Ophthalmic: Systemic bioavailability after topical ocular administration is very low (approximately 0.1-1% of the dose), but sufficient for local ocular effects. Oral bioavailability is not clinically relevant as drug is only used ophthalmically.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
No dose adjustment required in renal impairment; systemic exposure is minimal due to topical administration.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
No dose adjustment required in hepatic impairment; systemic exposure is minimal.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Safety and efficacy in pediatric patients have not been established; use is not recommended.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
No specific dose adjustment; dosing is identical to standard adult dosing.
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
No FDA black box warning.
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Increased bleeding time due to antiplatelet effect,Delayed healing or corneal adverse events including keratitis and corneal perforation,Cross-sensitivity with aspirin or other NSAIDs,Use with caution in patients with bleeding diatheses or concurrent anticoagulants
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
Hypersensitivity to nepafenac or any component of the formulation,History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
No clinically significant food interactions have been identified with ophthalmic nevanac. Systemic absorption is minimal, so dietary restrictions are not required.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: generally considered lower risk for teratogenicity, but avoid if possible. Third trimester: increased risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Ophthalmic use results in minimal systemic absorption, but theoretical risks remain. Use only if clearly needed.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
No data on nepafenac in breast milk. Ophthalmic administration yields negligible systemic concentrations. M/P ratio not determined. Considered likely compatible with breastfeeding due to minimal absorption, but caution advised.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
No dose adjustments are typically required due to ophthalmic administration; systemic exposure is negligible. However, avoid use in third trimester unless potential benefit outweighs risk. No pharmacokinetic changes in pregnancy necessitate dose adjustment for topical ophthalmic formulation.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Nevanac (nepafenac) is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic suspension indicated for pain and inflammation associated with cataract surgery. Its prodrug formulation enhances corneal penetration, with active metabolite amfenac inhibiting COX-1 and COX-2. Administer one drop three times daily starting 1 day prior to surgery, continuing on day of surgery and for 2 weeks postoperatively. Avoid concurrent use of other NSAIDs or corticosteroids to mitigate risk of corneal adverse events. Monitor for signs of corneal epithelial breakdown, especially in patients with compromised corneal innervation (e.g., diabetes, prior ocular surgery).
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
Wash hands before and after instilling the drop.,Remove contact lenses before use and wait 10 minutes after administering before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Apply one drop to the affected eye three times daily as directed, starting one day before cataract surgery.,Temporary blurred vision may occur; avoid driving or operating machinery until vision clears.,Notify your doctor if you experience eye pain, redness, sensitivity to light, or changes in vision.,Do not use other eye drops without consulting your doctor, especially other anti-inflammatory medications.,Store the bottle upright at room temperature, away from heat and light, and discard any unused suspension after the treatment period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CADUET vs NEVANAC, answered by our medical review team.
CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. NEVANAC is a NSAID Ophthalmic that works by Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CADUET and NEVANAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. The standard adult dose of NEVANAC is: One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CADUET and NEVANAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. NEVANAC is classified as Category C. Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.